| 0.5266 -0.167 (-24.12%) | 12-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.61 | 1-year : | 0.71 |
| Resists | First : | 0.52 | Second : | 0.61 |
| Pivot price | 0.52 | |||
| Supports | First : | 0.52 | Second : | 0.52 |
| MAs | MA(5) : | 0.52 | MA(20) : | 0.52 |
| MA(100) : | 0.52  |
MA(250) : | 3.16 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 25.1 | |||
| 52-week | High : | 9.88 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONCT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 140 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.53 - 0.53 | 0.53 - 0.53 |
| Low: | 0.52 - 0.52 | 0.52 - 0.53 |
| Close: | 0.52 - 0.53 | 0.53 - 0.53 |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Tue, 01 Jul 2025
Oncternal's $68M Asset Sale Deal: Biotech Company Sells Cancer Programs Before Complete Shutdown - Stock Titan
Tue, 01 Jul 2025
ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations - Fierce Biotech
Tue, 01 Jul 2025
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations - GlobeNewswire
Fri, 07 Mar 2025
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
Mon, 25 Nov 2024
Oncternal shares to be delisted from Nasdaq - Investing.com
Sun, 15 Sep 2024
Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808 - CGTLive®
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.71e+006 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 757.2 % |
| Return on Equity (ttm) | -76.5 % |
| Qtrly Rev. Growth | 2.16e+006 % |
| Gross Profit (p.s.) | 482.13 |
| Sales Per Share | -86.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 14210 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|